John Mascarenhas, MD, MS: Continuing to Evaluate Pacritinib for Myelofibrosis
683 views · Published 6 December 2016 · 4:59 · Indexed 19 October 2026
Channel: American Society of Hematology · 2016 · Nonprofits & Activism
Dr. Mascharenhas discusses results from the randomized phase III PERSIST-2 trial of the JAK2 inhibitor pacritinib in patients with myelofibrosis and thrombocytopenia, which was put on clinical hold in February 2016.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding